Chordia Therapeutics (TSE:190A) 5-Year Yield-on-Cost %: 0.00 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:190A Chordia Therapeutics Inc TSE:190A
13 GF Score
Price 円82.00
! 1 Warning Sign
View Full Analysis

What is Chordia Therapeutics 5-Year Yield-on-Cost %?

Chordia Therapeutics TSE:190A 13 5-Year Yield-on-Cost % is 0.00 as of Aug. 21, 2026. GuruFocus rates TSE:190A with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 150 Biotechnology companies, Chordia Therapeutics ranks worse than 666666% on this metric.

Chordia Therapeutics's yield on cost for the quarter that ended in Feb. 2026 was 0.00.


The historical rank and industry rank for Chordia Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



TSE:190A's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.655
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Chordia Therapeutics  (TSE:190A) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Chordia Therapeutics 5-Year Yield-on-Cost % Related Terms


TSE:190A vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Chordia Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chordia Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chordia Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Chordia Therapeutics's 5-Year Yield-on-Cost % falls into.


TSE:190A
13GF Score
Chordia Therapeutics Inc TSE:190A
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chordia Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Chordia Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Chordia Therapeutics (TSE:190A) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 21, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chordia Therapeutics and its competitors. According to the industry distribution chart, Chordia Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry.
Is Chordia Therapeutics' 5-Year Yield-on-Cost % too high?
Chordia Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Chordia Therapeutics ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chordia Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chordia Therapeutics' 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chordia Therapeutics ranks #999999 out of 150 companies for 5-Year Yield-on-Cost %. This places Chordia Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.66, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chordia Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chordia Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chordia Therapeutics stock overvalued right now?
Chordia Therapeutics (TSE:190A) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Chordia Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chordia Therapeutics (TSE:190A), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chordia Therapeutics Business Description

Address 2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.
13GF Score

Get the complete analysis for TSE:190A

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円82.00
Price